JNJ vs PFE
Johnson & Johnson vs Pfizer Inc. · Updated Nov 9, 2026
JNJ — 12 winsPFE — 11 wins
Price Performance
JNJ +48.93%PFE +20.32%
Performance
| JNJ | PFE | |
|---|---|---|
| 1 Month | +7.22% | +5.10% |
| 3 Months | +5.04% | +8.10% |
| 6 Months | +24.26% | +13.86% |
| YTD | +32.89% | +17.43% |
| 1 Year | +47.85% | +18.81% |
| 3 Year | +67.59% | -14.70% |
| 5 Year | +68.58% | -18.89% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | +35.3% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
| PFE | +16.5% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
Valuation
| JNJ | PFE | |
|---|---|---|
| P/E Ratio | 31.79 | 22.32 |
| Forward P/E | 11.17 | 9.08 |
| PEG Ratio | 2.75 | -3.95 |
| P/S Ratio | 6.65 | 2.70 |
| P/B Ratio | 7.89 | 1.90 |
| EV/EBITDA | 22.48 | 16.96 |
Financials
| JNJ | PFE | |
|---|---|---|
| EPS (TTM) | $8.65 | $1.31 |
| Gross Margin | +71.49% | +67.26% |
| Operating Margin | +26.58% | +27.90% |
| Net Margin | +21.76% | +18.60% |
| ROE | +25.92% | +8.31% |
| ROA | +10.47% | +3.61% |
| Debt/Equity | 0.22 | 0.72 |
Growth
| JNJ | PFE | |
|---|---|---|
| Revenue Growth YoY | +9.91% | +5.37% |
| Revenue Growth QoQ | -2.04% | -17.69% |
| EPS Growth YoY | -52.86% | -9.55% |
| EPS Growth QoQ | +1.90% | +262.07% |
Technical
| JNJ | PFE | |
|---|---|---|
| RSI (14) | 55.78 | 47.93 |
| % From 20-Day SMA | +3.90% | -1.73% |
| % From 50-Day SMA | +3.47% | +1.73% |
| % From 200-Day SMA | +10.74% | +8.68% |
| % From 52-Week High | -2.48% | -7.00% |
| % From 52-Week Low | +48.56% | +23.79% |
Analyst Ratings
JNJ
Buy(25 analysts)
Strong SellHoldStrong Buy
Price Target
$285.31
+3.75% upside
PFE
Hold(17 analysts)
Strong SellHoldStrong Buy
Price Target
$31.13
+6.46% upside
Overview
| JNJ | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $640.75B | $170.99B |
| Shares Outstanding | 2.41B | 5.70B |
| Avg Volume (10D) | 7.60M | 41.30M |
| Dividend Yield | 1.98% | 5.73% |
Frequently Asked Questions
Is JNJ or PFE a better buy right now?
Based on 23 comparable metrics, JNJ leads in 12 categories while PFE leads in 11. JNJ has a consensus analyst rating with 25 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, JNJ or PFE?
Over the past year, JNJ returned +47.85% compared to PFE's +18.81%. In the short term (1 month), JNJ returned +7.22% vs PFE's +5.10%.
Is JNJ or PFE more expensive?
JNJ trades at a P/E of 31.79 compared to PFE's 22.32. On a price-to-sales basis, JNJ trades at 6.65x vs PFE's 2.70x. Forward P/E: JNJ at 11.17 vs PFE at 9.08.
Which stock has higher growth, JNJ or PFE?
JNJ's revenue grew +9.91% year-over-year compared to PFE's +5.37%. EPS growth: JNJ at -52.86% vs PFE at -9.55%.
Do JNJ and PFE pay dividends?
JNJ pays a dividend with a yield of 1.98%. PFE pays a dividend with a yield of 5.73%.
Which stock do analysts prefer, JNJ or PFE?
JNJ has 25 analysts with a target price of $285.31 (+3.75% upside). PFE has 17 analysts with a target of $31.13 (+6.46% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.